Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 38-43

  Merli, Francesco ^a   Luminari, Stefano ^b   Rossi, Giuseppe ^c   Mammi, Caterina ^a   Marcheselli, Luigi ^b   Ferrari, Angela ^a   Spina, Michele ^d   Tucci, Alessandra ^c   Stelitano, Caterina ^e   Capodanno, Isabella ^a   Fragasso, Alberto ^f   Baldini, Luca ^g   Bottelli, Chiara ^c   Montechiarello, Elisa ^e   Fogazzi, Stefano ^c   Lamorgese, Cinzia ^c   Cavalli, Lara ^c   Federico, Massimo ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Division of Hematology   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e Azienda Ospedaliera   (Italy)

^f Ospedale Madonna Delle Grazie   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

Chemotherapy; Comprehensive Geriatric Assessment (CGA); Diffuse large B cell lymphoma (DLBCL); Elderly patients; Frail patients; Rituximab

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADL DISABILITY; AGED; ARTICLE; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; COOKING; CORTICOSTEROID THERAPY; DAILY LIFE ACTIVITY; DEPRESSION; DIABETES MELLITUS; FEMALE; FOLLOW UP; FRAIL ELDERLY; GERIATRIC ASSESSMENT; GERIATRIC DISORDER; GROOMING; HEART DISEASE; HUMAN; HYPERTENSION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LAUNDRY; LIVER FAILURE; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONAL HYGIENE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEPSIS; SHOPPING; SUDDEN DEATH; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMANS; ITALY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOPLASM GRADING; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84891365733     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.788176     Document Type: Article

References (24)

1. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011; 117: 5019-5032.
2. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20-B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
4. Feugier P, Van Hoof A, Sebban C, et al. Long-Term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe D'Etude des Lymphomes de l' Adulte. J Clin Oncol 2005; 23: 4117-4126.
5. Balducci L, Ballester O F. Non-Hodgkin' s lymphoma in the elderly. Cancer Control 1996; 3: 5-14.
6. Balducci L, Lyman GH, Fabri PJ. Management of cancer in the aged. Compr Th er 1996; 22: 88-93.
7. Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results from the phase II EUR018 trial. Ann Oncol 2010; 21: 1492-1499.
8. Merli F, Bertini M, Luminari S, et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48: 367-373.
9. Zinzani PL, Gherlinzoni F, Storti S, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002; 13: 1364-1369.
10. Balducci L, Extermann M. Management of the frail person with advanced cancer. Crit Rev Oncol Hematol 2000; 33: 143-148.
11. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25: 1824-1831.
12. Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 2000; 35: 147-154.
13. Nabhan C, Smith SM, Helenowski I, et al. A nalysis of very elderly (-/-80 years) non-Hodgkin lymphoma: Impact of functional status and co-morbidities on outcome. Br J Haematol 2012; 156: 196-204.
14. Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly " fit " patients with diffuse large B-cell lymphoma: Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma 2012; 53: 581-588.
15. Miller TA. A manual of guidelines for scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Pittsburg, PA: University of Pittsburg; 1991.
16. Ederer F, Heise H. I nstructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. Bethesda, MD: End Results Evaluation Section, National Cancer Institute; 1959. Apredictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
17. Sonneveld P, d e Ridder M, Van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530-2539.
18. Wang R, Gross CP, Halene S, et al. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009; 33: 1594-1598.
19. Sorror ML. Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program 2010: 237-247.
20. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: Outcomes and prognostic factors in the modern era. Blood 2012; 119: 692-695.
21. Maartense E, Kluin-Nelemans HC, le Cessie S, et al. Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age. Cancer 2000; 89: 2667-2676.
22. Bertini M, Boccomini C, Calvi R. The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma 2001; 1: 278-284.
23. Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefi t from aggressive therapy. Cancer 2009; 115: 4547-4553.
24. Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113: 3896-3902.